Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Glioblastoma 3Advanced Solid Tumours 3Solid Tumors 2Advanced Malignant Solid Neoplasm 2Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Rhabdomyosarcoma 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pinealoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Gliosarcoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Chromosome 5q Deletion Syndrome 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Astrocytoma 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × adavosertib × Clear all
NCT01357161 2023-09-21

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Merck Sharp & Dohme LLC

Phase 2 Completed
136 enrolled 15 charts
Gynecologic

Ovarian Neoplasms

NCT02482311 2023-07-03

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
92 enrolled
BreastGynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02610075 2023-07-03

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

AstraZeneca

Phase 1 Completed
62 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡